Ran Zheng
Director/Board Member bij CARIBOU BIOSCIENCES, INC.
Vermogen: - $ op 31-03-2024
Profiel
Ran Zheng is currently the Chief Executive Officer & Director at Landmark Bio PBLLC and an Independent Director at Caribou Biosciences, Inc. Previously, she worked as the Vice President-Development Supply Chain at Amgen, Inc. and as the Chief Technical Officer at Orchard Therapeutics Plc.
She received a graduate degree from the University of Minnesota and an undergraduate degree from Beijing Forestry University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 20-02-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Ran Zheng
| Bedrijven | Functie | Begin |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Director/Board Member | 24-09-2021 |
| Landmark Bio PBLLC | Chief Executive Officer | 01-03-2021 |
Eerdere bekende functies van Ran Zheng
| Bedrijven | Functie | Einde |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 01-02-2021 |
| AMGEN INC. | Corporate Officer/Principal | - |
Opleiding van Ran Zheng
| University of Minnesota | Graduate Degree |
| Beijing Forestry University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
| Landmark Bio PBLLC |
